BioSpace News Archive

The University of Oxford and Sound Pharmaceuticals, are pleased to announce the successful completion of a Phase 2a study testing SPI-1005 as a new treatment for bipolar disorder.

Nevro Corp., a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced that Nevro Chairman, CEO and President D. Keith Grossman is scheduled to speak at the following upcoming virtual investor conferences:.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that it will be presenting two abstracts at the American Society of Clinical Oncology Virtual Scientific Program to be held from May 29 to May 31, 2020.

Bruker Corporation announced the successful installation and customer acceptance of the world’s first Avance™ NEO 1.2 GHz NMR system at the CERM of the University of Florence.

CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, and its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, announced the promotion of Chief Operating Officer Vincent J. Capponi to President and COO, effective immediately.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, reported key business updates and financial results for the quarter ended March 31, 2020.

Aleafia Health Inc.’s (TSX: ALEF, OTC: ALEAF) (“Aleafia Health” or the “Company”) wholly owned subsidiary Emblem Cannabis Corp. (“Emblem”) has secured a Health Canada Licence Amendment for its Paris Facility’s 30,000 sq. ft. Phase II expansion, entirely dedicated to the extraction, production, packaging and distribution of finished cannabis products.

BiondVax Pharmaceuticals Ltd., developer of the universal influenza vaccine candidate M-001, published a reminder that its publicly traded warrants will expire, according to their terms, on May 15, 2020.

Antibe Therapeutics Inc. provides an update on the timing of top-line results for the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346.

Company ends Phase 4 observational registry early as data achieved statistical significance for non-inferiority in premature neonates compared to term and near-term neonates at planned interim analysis